This HTML5 document contains 64 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n20http://linked.opendata.cz/resource/AHFS/
foafhttp://xmlns.com/foaf/0.1/
n11http://linked.opendata.cz/resource/drugbank/dosage/
n10http://linked.opendata.cz/resource/drugbank/drug/DB08877/identifier/kegg-drug/
n14http://www.rxlist.com/
n8http://linked.opendata.cz/resource/drugbank/drug/DB08877/identifier/drugbank/
n17http://bio2rdf.org/drugbank:
n4http://linked.opendata.cz/resource/drugbank/drug/DB08877/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n18http://www.drugs.com/mtm/
n15http://linked.opendata.cz/resource/drugbank/patent/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
owlhttp://www.w3.org/2002/07/owl#
n5http://linked.opendata.cz/ontology/drugbank/
n12http://linked.opendata.cz/resource/drugbank/drug/DB08877/identifier/chebi/
n6http://linked.opendata.cz/resource/drugbank/property/
xsdhhttp://www.w3.org/2001/XMLSchema#
n7http://linked.opendata.cz/resource/drugbank/drug/DB08877/identifier/wikipedia/
n21http://linked.opendata.cz/resource/atc/
n19http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB08877
rdf:type
n5:Drug
n5:description
Ruxolitinib is a janus-associated kinase inhibitor indicated to treat bone marrow cancer, specifically intermediate or high-risk myelofibrosis. FDA approved on November 16, 2011.
n5:dosage
n11:271B5A04-363D-11E5-9242-09173F13E4C5 n11:271B5A05-363D-11E5-9242-09173F13E4C5 n11:271B5A06-363D-11E5-9242-09173F13E4C5 n11:271B5A07-363D-11E5-9242-09173F13E4C5 n11:271B5A03-363D-11E5-9242-09173F13E4C5
n5:generalReferences
# Cervantes F, Martinez-Trillos A: Myelofibrosis: an update on current pharmacotherapy and future directions. Expert Opin Pharmacother. 2013 May;14(7):873-84. doi: 10.1517/14656566.2013.783019. Epub 2013 Mar 21. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23514013 # Lexi-Comp, Inc. (Lexi-DrugsTM ). Lexi-Comp, Inc.; July, 2013. # Yang LP, Keating GM: Ruxolitinib: in the treatment of myelofibrosis. Drugs. 2012 Nov 12;72(16):2117-27. doi: 10.2165/11209340-000000000-00000. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/23061804
n5:group
approved
n5:halfLife
Mean elimination half-life, 15 mg, healthy subject = 2.8 hours.
n5:indication
Treatment of intermediate or high-risk myelofibrosis, including primary myelofibrosis, post-polycythemia vera (post-PV) myelofibrosis and post-essential thrombocythemia (post-ET) myelofibrosis. [Lexicomp] Myeolofibrosis is the proliferation of abnormal bone marrow stem cells which cause fibrosis (the excessive formation of connective tissue).
owl:sameAs
n17:DB08877
dcterms:title
Ruxolitinib
adms:identifier
n4:50881-025-60 n7:Ruxolitinib n8:DB08877 n10:D09959 n12:66919
n5:mechanismOfAction
Ruxolitinib is a kinase inhibitor that is selective for the Janus Associated Kinases (JAK) 1 and 2. These kinases are responsible for the mediation of cytokine and growth factor signalling which in turn effect immune function and hematopoiesis. The signalling process involves signal transducers and transcription activators (STAT) which modulate gene expression. Patients with myelofibrosis have abnormal JAK1 and JAK2 activity thus ruxolitinib works to regulate this.
n5:patent
n15:8415362 n15:7598257
n5:routeOfElimination
Eliminated via urine (74%, <1% as unchanged drug) and feces (22%, <1% as unchanged drug).
n5:synonym
INCB018424 INCB424
n5:toxicity
Thrombocytopenia was the dose-limiting toxicity.
n5:volumeOfDistribution
Terminal phase volume of distribution, 15 mg, healthy subject = 76.6 L.
n19:hasAHFSCode
n20:10-00
n5:foodInteraction
Take without regards to meals
n5:proteinBinding
97% protein bound, primarily to albumin.
n5:salt
foaf:page
n14:jakafi-drug.htm n18:ruxolitinib.html
n5:IUPAC-Name
n6:271B5A0C-363D-11E5-9242-09173F13E4C5
n5:InChI
n6:271B5A12-363D-11E5-9242-09173F13E4C5
n5:Molecular-Formula
n6:271B5A11-363D-11E5-9242-09173F13E4C5
n5:Molecular-Weight
n6:271B5A0E-363D-11E5-9242-09173F13E4C5
n5:Monoisotopic-Weight
n6:271B5A0F-363D-11E5-9242-09173F13E4C5
n5:SMILES
n6:271B5A10-363D-11E5-9242-09173F13E4C5
n5:Water-Solubility
n6:271B5A22-363D-11E5-9242-09173F13E4C5 n6:271B5A0A-363D-11E5-9242-09173F13E4C5
n5:logP
n6:271B5A0B-363D-11E5-9242-09173F13E4C5 n6:271B5A08-363D-11E5-9242-09173F13E4C5
n5:logS
n6:271B5A09-363D-11E5-9242-09173F13E4C5
n19:hasATCCode
n21:L01XE18
n5:H-Bond-Acceptor-Count
n6:271B5A18-363D-11E5-9242-09173F13E4C5
n5:H-Bond-Donor-Count
n6:271B5A19-363D-11E5-9242-09173F13E4C5
n5:InChIKey
n6:271B5A13-363D-11E5-9242-09173F13E4C5
n5:Polar-Surface-Area--PSA-
n6:271B5A14-363D-11E5-9242-09173F13E4C5
n5:Polarizability
n6:271B5A16-363D-11E5-9242-09173F13E4C5
n5:Refractivity
n6:271B5A15-363D-11E5-9242-09173F13E4C5
n5:Rotatable-Bond-Count
n6:271B5A17-363D-11E5-9242-09173F13E4C5
n5:absorption
Absorption is rapid and is not affected by food. Cmax, 15 mg, healthy subject = 649 nmol/L; Tmax, 15 mg, healthy subject = 1.5 hours; Ruxolitinib does not accumulate significantly.
n5:affectedOrganism
Humans and other mammals
n5:casRegistryNumber
941678-49-5
n5:clearance
15 mg, healthy subject = 18.7 L/h.
n5:Bioavailability
n6:271B5A1E-363D-11E5-9242-09173F13E4C5
n5:Ghose-Filter
n6:271B5A20-363D-11E5-9242-09173F13E4C5
n5:MDDR-Like-Rule
n6:271B5A21-363D-11E5-9242-09173F13E4C5
n5:Number-of-Rings
n6:271B5A1D-363D-11E5-9242-09173F13E4C5
n5:Physiological-Charge
n6:271B5A1C-363D-11E5-9242-09173F13E4C5
n5:Rule-of-Five
n6:271B5A1F-363D-11E5-9242-09173F13E4C5
n5:Traditional-IUPAC-Name
n6:271B5A0D-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-acidic-
n6:271B5A1A-363D-11E5-9242-09173F13E4C5
n5:pKa--strongest-basic-
n6:271B5A1B-363D-11E5-9242-09173F13E4C5